---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-362387"
form_type: "8-K"
ticker: "ALNY"
cik: "0001178670"
company_name: "ALNYLAM PHARMACEUTICALS, INC."
filed_at: "2021-12-20T23:59:59+00:00"
generated_at: "2026-06-27T23:35:59.068049+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Alnylam appoints Yvonne Greenstreet as CEO effective Jan 1, 2022; discloses compensation

## Summary
- Yvonne Greenstreet, formerly President and COO, becomes CEO on Jan 1, 2022.
- Annual base salary of $850,000; target bonus 100% of base salary for 2022 performance year.
- Initial equity: $5M stock option granting on Dec 31, 2021; additional $2.5M option and $7.5M PSUs in Feb 2022.
- $250,000 one-time relocation cash award with repayment obligation if termination for cause within 24 months.
- Severance: pre-Change-in-Control no cash severance but continued vesting for 2 years; post-CIC double trigger with 2x salary+bonus and full acceleration.

## SEC filing metadata
- accession: 0001193125-21-362387
- form_type: 8-K
- ticker: ALNY
- cik: 0001178670
- company_name: ALNYLAM PHARMACEUTICALS, INC.
- filed_at: 2021-12-20T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178670/000119312521362387/0001193125-21-362387-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178670/000119312521362387/d163524d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-362387
- JSON: https://secwatch.observer/filing/0001193125-21-362387.json
- Plain text: https://secwatch.observer/filing/0001193125-21-362387.txt

## Key facts
- Executive change
  Yvonne L. Greenstreet was appointed as Chief Executive Officer at ALNYLAM PHARMACEUTICALS, INC..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: Yvonne L. Greenstreet, MBChB, MBA, Alnylam Pharmaceuticals, Inc.’s (the “Company”) current President and Chief Operating Officer, has been appointed Chief Executive Officer of the Company effective January 1, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1178670/000119312521362387/0001193125-21-362387-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.